KIT D816V
|
hematologic cancer
|
resistant
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) did not inhibit Kit phosphorylation or growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).
|
31309543
|
KIT D816V
|
hematologic cancer
|
predicted - sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) demonstrated moderate inhibition of Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).
|
31309543
|
KIT D816V
|
acute myeloid leukemia
|
sensitive
|
Avapritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Ayvakit (avapritinib) inhibited Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).
|
31309543
|
KIT D816V
|
hematologic cancer
|
resistant
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Nexavar (sorafenib) did not inhibit Kit phosphorylation or growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).
|
31309543
|
CBL Y371H FLT3 wild-type
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).
|
31309543
|
FLT3 D835Y
|
hematologic cancer
|
resistant
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3 D835Y were resistant to Nexavar (sorafenib)-induced growth inhibition in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins
|
acute myeloid leukemia
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) inhibited Flt3 phosphorylation and growth of acute myeloid leukemia cell lines harboring FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).
|
31309543
|
FLT3 D835Y
|
hematologic cancer
|
conflicting
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) inhibited growth of transformed hematologic cells expressing FLT3 D835Y in culture (PMID: 31309543).
|
31309543
|
KIT D816V
|
hematologic cancer
|
sensitive
|
Avapritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Ayvakit (avapritinib) inhibited Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).
|
31309543
|
CBL Q365_E366insSK FLT3 wild-type
|
hematologic cancer
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins
|
hematologic cancer
|
decreased response
|
Avapritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Ayvakit (avapritinib) inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture with reduced potency compared to other kinase inhibitors (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins
|
hematologic cancer
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins
|
acute myeloid leukemia
|
sensitive
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Nexavar (sorafenib) inhibited Flt3 phosphorylation and growth of acute myeloid leukemia cell lines harboring FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).
|
31309543
|
CBL Q365_E366insSK FLT3 wild-type
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins FLT3 F691L
|
hematologic cancer
|
predicted - resistant
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Crenolanib-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).
|
31309543
|
CBL Y371H FLT3 wild-type
|
hematologic cancer
|
sensitive
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins
|
acute myeloid leukemia
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Crenolanib inhibited Flt3 phosphorylation and growth of acute myeloid leukemia cell lines harboring FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).
|
31309543
|
FLT3 D835Y
|
hematologic cancer
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing FLT3 D835Y in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins
|
acute myeloid leukemia
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) inhibited Flt3 phosphorylation and growth of acute myeloid leukemia cell lines harboring FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins
|
hematologic cancer
|
sensitive
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins FLT3 F691L
|
hematologic cancer
|
resistant
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were resistant to Nexavar (sorafenib)-induced growth inhibition in culture (PMID: 31309543).
|
31309543
|
CBL Y371H FLT3 wild-type
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical |
Actionable |
In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture, reduced leukemia burden and prolonged survival in animal models (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins FLT3 F691L
|
hematologic cancer
|
decreased response
|
Avapritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Ayvakit (avapritinib)-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins
|
acute myeloid leukemia
|
resistant
|
Avapritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Ayvakit (avapritinib) did not inhibit Flt3 phosphorylation or growth of acute myeloid leukemia cell lines harboring FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).
|
31309543
|
KIT D816V
|
hematologic cancer
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Crenolanib inhibited Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).
|
31309543
|
KIT D816V
|
acute myeloid leukemia
|
resistant
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) did not inhibit Kit phosphorylation or growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).
|
31309543
|
KIT D816V
|
acute myeloid leukemia
|
resistant
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Nexavar (sorafenib) did not inhibit Kit phosphorylation or growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).
|
31309543
|
CBL Q365_E366insSK FLT3 wild-type
|
hematologic cancer
|
decreased response
|
Avapritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Ayvakit (avapritinib) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture with reduced potency compared to other kinase inhibitors (PMID: 31309543).
|
31309543
|
CBL Q365_E366insSK FLT3 wild-type
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).
|
31309543
|
KIT D816V
|
acute myeloid leukemia
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Crenolanib inhibited Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).
|
31309543
|
KIT D816V
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) inhibited Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins FLT3 F691L
|
hematologic cancer
|
resistant
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Vanflyta (quizartinib)-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins FLT3 F691L
|
hematologic cancer
|
resistant
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Xospata (gilteritinib)-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).
|
31309543
|
FLT3 D835Y
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing FLT3 D835Y in culture (PMID: 31309543).
|
31309543
|
CBL Q365_E366insSK FLT3 wild-type
|
hematologic cancer
|
sensitive
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).
|
31309543
|
FLT3 D835Y
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing FLT3 D835Y in culture (PMID: 31309543).
|
31309543
|
FLT3 D835Y
|
hematologic cancer
|
resistant
|
Avapritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3 D835Y were resistant to Ayvakit (avapritinib)-induced growth inhibition in culture (PMID: 31309543).
|
31309543
|
CBL Y371H FLT3 wild-type
|
hematologic cancer
|
decreased response
|
Avapritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Ayvakit (avapritinib) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture with reduced potency compared to other kinase inhibitors (PMID: 31309543).
|
31309543
|
CBL Q365_E366insSK FLT3 wild-type
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).
|
31309543
|
KIT D816V
|
acute myeloid leukemia
|
predicted - sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) demonstrated moderate inhibition of Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).
|
31309543
|
CBL Y371H FLT3 wild-type
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).
|
31309543
|
CBL Y371H FLT3 wild-type
|
hematologic cancer
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins FLT3 F691L
|
hematologic cancer
|
resistant
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) did not inhibit growth of transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L in culture (PMID: 31309543).
|
31309543
|
FLT3 exon 14 ins
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).
|
31309543
|
KIT D816V
|
acute myeloid leukemia
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) inhibited Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).
|
31309543
|